Biologics and ConjugatesJul 30, 2026
Antibody-Oligonucleotide Conjugates: From Conjugation Strategy to Purification and Analytical Control
Antibody-Oligo Conjugate (AOC), as an innovative targeted gene therapy biopharmaceutical, effectively integrates the targeting advantages of monoclonal antibodies and the gene regulatory functions of oligonucleotides, helping address key limitations in the inherent of traditional antibody drugs and nucleic acid drugs, and showing substantial clinical
Case Studies & WhitepapersJun 30, 2026
FAQ: Applications of Different Synthetic Strategies for Peptide Process Development
Applications of Different Peptide Synthesis Strategies in Process Development
Biologics and ConjugatesJun 25, 2026
FAQ: CMC Development Strategy for Oligonucleotides in AOCs
•How to reduce hydrolysis during SMCC conjugation? •Can SMCC conjugate after hydrolytic ring-opening? •How is OAR1 regulated during random SMCC conjugation? •Which strategy is preferred for siRNA linker conjugation: pre-annealing or post-annealing conjugation?
Small MoleculesJun 12, 2026
Biocatalysis Enables The Efficient Synthesis and Commercial Application of Unnatural Amino Acids (UAAs)
Biocatalysis is a pivotal enabler for the sustainable synthesis of unnatural amino acids. By integrating novel enzymes discovery, multi-enzyme cascades and chemo-enzymatic routes, Porton has established practical capabilities to address industry challenges in substrate specificity and enzyme stability. Moving forward, Porton remains dedicated to bridging the gap between laboratory innovation and industrial-scale application, providing customers with reliable, scalable and atom-efficient solutions for UAA production.
Small MoleculesMay 27, 2026
Dry Particle Coating for the Enhancement of API Flowability and Bulk Density
The mechanism of the dry particle coating and a short description of four coating techniques including comil, LabRAM, a high shear mixer and a jet mill are provided.
Case Studies & WhitepapersMay 22, 2026
FAQ: Process Development Strategies for AOC Drugs
What is the mainstream conjugation process for antibodies and siRNA?
Case Studies & WhitepapersMay 22, 2026
Process Development and Quality Research Strategy for Dual-Payload Conjugated Drugs
Process Development and Quality Research Strategy for Dual-Payload Conjugated Drugs
Biologics and ConjugatesMar 11, 2026
Optimization of Synthetic Process and Metal-Chelation Impurity Control Strategy for Complex Peptide-based RDCs
It fully demonstrates the strength of Porton's one-stop RDC service platform, excellent project management capabilities, and efficient production and operation.
Small MoleculesFeb 28, 2026
The Perfect Integration of Immobilized Enzymes and Flow Chemistry: A Powerful Booster for the Commercialization of Biocatalysis Technology
Adhering to Porton’s core value of “Pursuing Excellence”, Porton biocatalysis team has designated "enzyme immobilization technology and its industrialization" as a core strategic technology.
